| Â | anti-V3 mAbs | Â |
|---|
# | Virus ID | Tier | Clade | 277 | 903 | 904 | 447-52D | 1418 |
|---|
1 |
MW965
| 1 | C |
0.34
|
0.15
|
<0.1
|
<0.1
| >30 |
2 |
DJ263
| 1 | A |
8.2
|
1.7
|
0.4
|
<0.1
| >30 |
3 |
SF162
| 1 | B | >30 | >30 | >30 |
<0.1
| >30 |
4 |
JR-CSF
| 1 | B | >30 | >30 | >30 |
0.3
| >30 |
5 |
92RW009
| 1 | A | >30 | >30 | >30 | >30 | >30 |
6 |
HIV-001428
| 2 | C | >30 |
15.4
|
22.8
| >30 | >30 |
7 |
ZM109F.PB4
| 2 | C | >30 | >30 | >30 | >30 | >30 |
8 |
ZM233M.PB6
| 2 | C | >30 | >30 | >30 | >30 | >30 |
9 |
Du156.12
| 2 | C | >30 | >30 | >30 | >30 | >30 |
10 |
JRFL
| 2 | B | >30 | >30 | >30 | 20 | >30 |
11 |
RHPA4259.7
| 2 | B | >30 | >30 | >30 | >30 | >30 |
- The cross neutralizing activities of mAbs generated from Indian patients along with 447-52D (also an anti-V3 antibody), were evaluated against the tier 1 and 2 subtype_A, B, C viruses indicated on the left. The antibodies are shown with antibody IDs (numerical values in bold) at the top of each column. Human anti-parvovirus B19 mAb 1418 was used as negative control. The numerical values in the boxes below are the 50% neutralization titers (IC50) defined as the concentration (μg/ml) of mAb which neutralized 50% of viral infection in the assay. For clarity, this information is coded: IC50 < 1 μg/ml; (Bold), IC50 > 1 μg/ml; (Italic) and >30, where IC50 was not reached. Each experiment was performed at least two independent times.
